To all shareholders and shareholder representatives:
LanDian Technology Group Co., Ltd. 2025 Annual Report of Independent Director (Yuan Lin)
In 2025, as an independent director of LanDian Technology Group Co., Ltd. (hereinafter referred to as the "Company" or "LanDian Technology"), I have diligently and conscientiously performed my duties as an independent director in strict accordance with the "Company Law," the "Stock Listing Rules of the Shenzhen Stock Exchange," the "Shenzhen Stock Exchange Main Board Listed Company's Standardized Operation Guidance No. 1," the "Measures for the Administration of Independent Directors of Listed Companies," and other relevant laws, regulations, normative documents, as well as the "Articles of Association," and the "Work System for Independent Directors of the Company," and the "Special Meeting Work System for Independent Directors of the Company." During the reporting period, I actively attended Company board meetings, special committee meetings, and independent director special meetings, and attended shareholder meetings. I conscientiously reviewed the proposals submitted for deliberation, voted independently, objectively, and prudently, fully leveraging the role of independent directors, and supervised the standardized operation of the Company, effectively safeguarding the legitimate rights and interests of the Company and all shareholders, especially small and medium shareholders.
Here is my performance report for 2025:
I. Basic Information
I, Yuan Lin, born in November 1964, hold a Ph.D. in Law. I am currently a professor and doctoral supervisor at the Law School of Southwest University of Political Science and Law, and the Director of the Research Center for the Protection of Rights and Interests of Special Groups and Crime Prevention. I also serve as a director of the China Banking Law Society, the director of the Professional Committee on Crime Governance for Special Groups of the Chinese Criminology Society, a counselor for the Chongqing Municipal People's Government, and an independent director for LanDian Technology, Chongqing Zhifei Biological Products Co., Ltd., Chongqing Boton Pharmaceutical Technology Co., Ltd., and Kaisa Group Holdings Limited (listed in Hong Kong).
I have served as an independent director of the Company since October 2023, concurrently serving as the Chairman of the Nomination, Remuneration and Appraisal Committee of the Board of Directors and a member of the Audit Committee of the Board of Directors. I do not hold any positions in the Company's principal shareholders, and I have no relationship of interest with the Company or its principal shareholders, nor any other relationship that may hinder independent and objective judgment, and there are no other circumstances affecting the independence of independent directors. This complies with the requirements of the "Measures for the Administration of Independent Directors of Listed Companies," the "Stock Listing Rules of the Shenzhen Stock Exchange," and the "Shenzhen Stock Exchange Main Board Listed Company's Standardized Operation Guidance No. 1" and other relevant laws and regulations for independent directors.
II. Performance in 2025
(I) Attendance at Board and Shareholder Meetings
In 2025, I attended all board and shareholder meetings either in person or via communication. I carefully reviewed all proposals submitted for deliberation, communicated and exchanged with the Company's management, other directors, relevant staff, and intermediary agency personnel, and gained a thorough understanding of the content and background of the proposals. Based on my professional knowledge and independent judgment, I made prudent decisions. In 2025, I voted in favor of all proposals deliberated by the Company's board of directors, with no opposing or abstaining votes. I believe that the convening, holding, and voting procedures of the Company's board and shareholder meetings in 2025 comply with relevant laws, regulations, and normative documents.
The specific situation of my attendance at board and shareholder meetings in 2025 is as follows: